Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago.
A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
1. Patients with pemphigus treated with first-line rituximab showed sustained complete remission rates without corticosteroids for up to 7 years post-treatment 2. High-risk patients for pemphigus relapse could be assessed with enzyme-linked immunosorbent assay (ELISA) values of anit-Dsg antibodies. Evidence Rating Level: 1 (Excellent) Study Rundown: Pemphigus is a life-threatening rare autoimmune bullous disease affecting